- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01077505
An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
June 13, 2017 updated by: GlaxoSmithKline
An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK716155 in Healthy Adult Female Subjects
This study will be an open-label study to evaluate the effect of albiglutide on the pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon).
The primary objective of this study is to demonstrate the lack of effect of albiglutide doses on the pharmacokinetics of norethindrone and ethinyl estradiol in healthy female subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study will be an open-label study in at least one center to evaluate the effect of albiglutide administration on the pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon).
The primary objective of this study is to demonstrate the lack of effect of albiglutide doses on the pharmacokinetics of norethindrone and ethinyl estradiol in healthy female subjects.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78744
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Healthy female subjects, defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, clinical laboratory tests, and 12-lead ECG;
- Women of childbearing potential must use protocol-defined contraceptive methods;
- BMI is 19 to 30 kg/m2 and body weight ≥50 kg (110 lbs) and <114 kg (<250 lbs);
- Aspartate aminotransferase (AST), ALT, alkaline phosphatase, and bilirubin is </=1.5 × ULN;
Exclusion Criteria:
- Any clinically relevant abnormality identified on the screening medical assessment, laboratory examination, or ECG;
- Blood pressure ≥140/90 mm Hg or heart rate >100 beats/minute at Screening;
- Corrected QT (QTc) intervals >450 msec (per ECG machine interpretation);
- Pregnant or nursing females;
- A positive prestudy hepatitis B surface antigen, positive hepatitis C antibody, or HIV result within 3 months of Screening;
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones);
- Smoking or using any nicotine products, including smoking cessation patches containing any amount of nicotine within the 6 months before Screening;
- Women of childbearing potential who are unwilling or unable to use an appropriate method of contraception;
- Subjects have participated in a clinical trial and have received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer);
- History of substance abuse within the past year as determined by the investigator;
- History of alcohol abuse defined as an average weekly intake of >7 drinks;
- Positive urine drug screen at Screening or predose during the Run-in Period and on Day 1 of Periods 1 and 2;
- Use of prescription or nonprescription drugs, vitamins, dietary/herbal supplements including St. John's Wort, nonsteroidal antiinflammatory medications, and aspirin within 14 days or 5 half-lives, whichever is longer prior to the first dose of investigational product;
- Willing to refrain from consuming grapefruit or cranberry products (such as juice, fruit, or nutritional supplements) at any time during participation in the study;
- Donation of blood in excess of 500 mL within 56 days prior to dosing or intention of donating in the month after completing the study;
- History of thyroid dysfunction or an abnormal (i.e., outside normal reference range) thyroid function test assessed by thyroid stimulating hormone (TSH) at Screening;
- History of drug allergy or other allergy, which, in the opinion of the responsible study physician, contradicts the subject's participation;
- History of any condition that would contraindicate OC administration (including hypertension, stroke, ischemic heart disease, venous thromboembolism, carcinoma of the breast, etc.);
- History of type 1 or 2 diabetes mellitus;
- History of migraine if aged >35 years or has focal symptoms associated with migraine;
- Any condition that would affect drug transit time or absorption (e.g., gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, chronic diarrhea, vagotomy, chronic gastroesophageal reflux disease, malabsorption, colostomy, Crohn's disease, ulcerative colitis, or celiac sprue); or
- Previous or current receipt of exenatide or any other GLP 1 agonist;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: albiglutide
albiglutide 50mg weekly
|
albiglutide 50mg weekly subcutaneous injection
Oral contraceptive (Brevicon)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC0-24 of norethindrone and ethinyl estradiol after OC alone in Period 1 and after OC with albiglutide in Period 2.
Time Frame: Day 21
|
Day 21
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax, Cmin, tmax, and t½ of norethindrone and ethinyl estradiol after OC alone on Day 21 of Period 1 and after OC with albiglutide on Day 21 of Period 2.
Time Frame: Day 21 of each period.
|
Day 21 of each period.
|
Predose serum levels of LH and FSH after OC alone and after OC with albiglutide.
Time Frame: Days 1 and 11 through 14 of each period.
|
Days 1 and 11 through 14 of each period.
|
Predose serum levels of progesterone after OC alone and after OC with albiglutide.
Time Frame: Day 21 of each period.
|
Day 21 of each period.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Young MA, Wald JA, Matthews JE, Scott R, Hodge RJ, Zhi H, Reinhardt RR. Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Postgrad Med. 2014 Nov;126(7):84-97. doi: 10.3810/pgm.2014.11.2836.
- Bush M, Scott R, Watanalumlerd P, Zhi H, Lewis E. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgrad Med. 2012 Nov;124(6):55-72. doi: 10.3810/pgm.2012.11.2613.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 15, 2010
Primary Completion (Actual)
November 24, 2010
Study Completion (Actual)
November 24, 2010
Study Registration Dates
First Submitted
February 25, 2010
First Submitted That Met QC Criteria
February 25, 2010
First Posted (Estimate)
March 1, 2010
Study Record Updates
Last Update Posted (Actual)
June 14, 2017
Last Update Submitted That Met QC Criteria
June 13, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Contraceptive Agents, Hormonal
- Reproductive Control Agents
- Contraceptives, Oral, Combined
- Contraceptive Agents, Female
- Incretins
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Contraceptives, Oral, Sequential
- Contraceptive Agents
- Contraceptives, Oral
- rGLP-1 protein
- Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination
Other Study ID Numbers
- 107032
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Individual Participant Data Set
Information identifier: 107032Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 107032Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 107032Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 107032Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 107032Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 107032Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 107032Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on albiglutide
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineDuke Clinical Research InstituteCompletedDiabetes MellitusUnited States, Argentina, Germany, Poland, Russian Federation, Spain, Taiwan, Czechia, Hungary, Italy, Ukraine, Belgium, Netherlands, South Africa, Sweden, Thailand, Korea, Republic of, Mexico, Bulgaria, Hong Kong, Peru, Philippines, Gree... and more
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States, Mexico, South Africa
-
GlaxoSmithKlinePPDWithdrawn
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States, South Africa
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States
-
Horizon Pharma USA, Inc.CompletedCystinosisFrance, United States, Netherlands
-
GlaxoSmithKlineWithdrawnDiabetes Mellitus, Type 2United States